Technological Innovations in Behavioral Treatments for Cigarette Smoking
|ClinicalTrials.gov Identifier: NCT00926939|
Recruitment Status : Completed
First Posted : June 24, 2009
Last Update Posted : April 14, 2015
|Condition or disease||Intervention/treatment||Phase|
|Cigarette Smoking||Behavioral: Reinforcement for the abstinence of smoking Behavioral: Reinforcement for submission of videos with CO sample||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||96 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Single (Care Provider)|
|Official Title:||Technological Innovations in Behavioral Treatments for Cigarette Smoking|
|Study Start Date :||June 2009|
|Actual Primary Completion Date :||May 2014|
|Actual Study Completion Date :||August 2014|
Experimental: Abstinence Contingent (AC)
This group will receive vouchers contingent on smoking reduction and smoking abstinence (confirmed through video submissions). Abstinence is defined as a CO sample of 4ppm or less.
Behavioral: Reinforcement for the abstinence of smoking
Participants in this intervention group will receive vouchers contingent upon a CO sample of 4ppm or less.
Experimental: Submission Contingent (SC)
This group receives vouchers for submitting videos of their CO breath test.
Behavioral: Reinforcement for submission of videos with CO sample
This intervention group will receive vouchers contingent on their submission of videos of their CO breath tests.
- CO sample of ≤ 4ppm [ Time Frame: 4 weeks, 7 weeks during intervention; 3 months and 6 months after intervention ]
- Participant reporting not smoking, not even a puff in the last 7 days. [ Time Frame: 4 weeks, 7 weeks during intervention; 3 months and 6 months after intervention ]
- Twice-daily breath CO samples obtained during treatment period. [ Time Frame: First 4 weeks of treatment ]
- The longest duration of sustained abstinence based on the twice-daily breath samples during the treatment period. [ Time Frame: First 4 weeks of treatment ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00926939
|United States, New York|
|National Development and Research Institutes|
|New York City, New York, United States, 10010|
|Principal Investigator:||Jesse Dallery, PhD||National Development and Research Institutes, Inc.|